+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Epilepsy Drugs Market Size, Share & Trends Analysis Report by Product (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), Region, and Segment Forecasts, 2023-2030

  • PDF Icon

    Report

  • 91 Pages
  • December 2023
  • Region: Global
  • Grand View Research
  • ID: 5921034
Description Jump to:
The global epilepsy drugs market size is expected to reach USD 15.35 billion by 2030, registering a CAGR of 5.1% from 2023 to 2030. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness trainingto the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.

Epilepsy Drugs Market Report Highlights

  • Second generation anti-epileptics are expected to be the second-fastest-growing segment. This segment includes Lamotrigine (Lamictal), Levetiracetam (Keppra), Brivaracetam (Briviact), and Perampanel (Fycompa).
  • The third generation anti-epileptics segment accounted for the largest revenue share of around 39.3% in 2022. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.
  • North America dominated the market with the largest revenue share of around 45% in 2022. The high prevalence of epilepsy in the region, with a significant number of people affected by the condition, is a major driving factor for the epilepsy drugs market.
  • Asia-Pacific is estimated to expand at the highest CAGR of 6.3% over the forecast period. The presence of favorable government initiatives such as the Intersectoral Global Action Plan on Epilepsy, Global Campaign Against Epilepsy, and others, as well as the launch of new-generation anti-epileptic drugs are the drivers expected to propel the growth of this market in the region.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Regional outlook
2.3. Competitive Insights
Chapter 3. Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Penetration & Growth Prospect Mapping
3.5. Global Epilepsy Drug Market Analysis Tools
3.5.1. Industry Analysis - Porter’s Five Forces
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
Chapter 4. Epilepsy Drugs Market: Product Estimates & Trend Analysis
4.1. Epilepsy Drug Market: Key Takeaways
4.2. Epilepsy Drug Market: Product Movement & Market Share Analysis, 2022 & 2030
4.3. First Generation Anti-epileptics
4.3.1. First generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Second Generation Anti-epileptics
4.4.1. Second generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Third Generation Anti-epileptics
4.5.1. Third generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Epilepsy Drugs Market: Regional Estimates & Trend Analysis, by Drug
5.1. Regional Outlook
5.2. Epilepsy Drug Market by Region: Key Marketplace Takeaways
5.3. North America
5.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.3.2. U.S.
5.3.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.3.3. Canada
5.3.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.4. Europe
5.4.1. UK
5.4.1.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.4.2. Germany
5.4.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.4.3. France
5.4.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.4.4. Italy
5.4.4.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.4.5. Spain
5.4.5.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.4.6. Sweden
5.4.6.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.4.7. Norway
5.4.7.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.4.8. Denmark
5.4.8.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.5. Asia-Pacific
5.5.1. Japan
5.5.1.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.5.2. China
5.5.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.5.3. India
5.5.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.5.4. Australia
5.5.4.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.5.5. Thailand
5.5.5.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.5.6. South Korea
5.5.6.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.6. Latin America
5.6.1. Brazil
5.6.1.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.6.2. Mexico
5.6.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.6.3. Argentina
5.6.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.7. MEA
5.7.1. Saudi Arabia
5.7.1.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.7.2. South Africa
5.7.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.7.3. UAE
5.7.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.7.4. Kuwait
5.7.4.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Market Participant Categorization
6.2.1. UCB S.A., Belgium
6.2.1.1. Company Overview
6.2.1.2. Financial Performance
6.2.1.3. Product Benchmarking
6.2.1.4. Strategic Initiatives
6.2.2. Sanofi
6.2.2.1. Company Overview
6.2.2.2. Financial Performance
6.2.2.3. Product Benchmarking
6.2.2.4. Strategic Initiatives
6.2.3. Pfizer, Inc.
6.2.3.1. Company Overview
6.2.3.2. Financial Performance
6.2.3.3. Product Benchmarking
6.2.3.4. Strategic Initiatives
6.2.4. Otsuka America Pharmaceutical, Inc.
6.2.4.1. Company Overview
6.2.4.2. Financial Performance
6.2.4.3. Product Benchmarking
6.2.4.4. Strategic Initiatives
6.2.5. Eisai Co., Ltd.
6.2.5.1. Company Overview
6.2.5.2. Financial Performance
6.2.5.3. Product Benchmarking
6.2.5.4. Strategic Initiatives
6.2.6. Novartis AG
6.2.6.1. Company Overview
6.2.6.2. Financial Performance
6.2.6.3. Product Benchmarking
6.2.6.4. Strategic Initiatives
6.2.7. Abbott Laboratories, Inc.
6.2.7.1. Company Overview
6.2.7.2. Financial Performance
6.2.7.3. Product Benchmarking
6.2.7.4. Strategic Initiatives
6.2.8. Sanofi Aventis S.A.
6.2.8.1. Company Overview
6.2.8.2. Financial Performance
6.2.8.3. Product Benchmarking
6.2.8.4. Strategic Initiatives
6.2.9. GlaxoSmithKline plc
6.2.9.1. Company Overview
6.2.9.2. Financial Performance
6.2.9.3. Product Benchmarking
6.2.9.4. Strategic Initiatives
6.2.10. Sunovion Pharmaceuticals, Inc.
6.2.10.1. Company Overview
6.2.10.2. Financial Performance
6.2.10.3. Product Benchmarking
6.2.10.4. Strategic Initiatives
6.2.11. Jazz Pharmaceuticals plc
6.2.11.1. Company Overview
6.2.11.2. Financial Performance
6.2.11.3. Product Benchmarking
6.2.11.4. Strategic Initiatives
6.2.12. Neurelis, Inc.
6.2.12.1. Company Overview
6.2.12.2. Financial Performance
6.2.12.3. Product Benchmarking
6.2.12.4. Strategic Initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 North America epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 3 North America epilepsy drugs market, by country, 2018-2030 (USD Million)
Table 4 U.S. epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 5 Canada epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 6 Europe epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 7 Europe epilepsy drugs market, by country, 2018-2030 (USD Million)
Table 8 Germany epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 9 UK epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 10 France epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 11 Italy epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 12 Spain epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 13 Sweden epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 14 Norway epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 15 Denmark epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 16 Asia-Pacific epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 17 Asia-Pacific epilepsy drugs market, by country, 2018-2030 (USD Million)
Table 18 China epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 19 Japan epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 20 India epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 21 Thailand epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 22 Australia epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 23 South Korea epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 24 Latin America epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 25 Latin America epilepsy drugs market, by country, 2018-2030 (USD Million)
Table 26 Brazil epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 27 Mexico epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 28 Argentina epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 29 Middle East and Africa epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 30 Middle East and Africa epilepsy drugs market, by country, 2018-2030 (USD Million)
Table 31 South Africa epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 32 Saudi Arabia epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 33 UAE epilepsy drugs market, by product, 2018-2030 (USD Million)
Table 34 Kuwait epilepsy drugs market, by product, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value-chain-based sizing & forecasting
Figure 6 QFD modeling for market share assessment
Figure 7 Market formulation & validation
Figure 8 Epilepsy drug market: Market outlook
Figure 9 Epilepsy drug market: Competitive insights
Figure 10 Parent market outlook
Figure 11 Related/ancillary market outlook
Figure 12 Penetration and growth prospect mapping
Figure 13 Industry value chain analysis
Figure 14 Epilepsy drug market driver impact
Figure 15 Epilepsy drug market restraint impact
Figure 16 Epilepsy drug market strategic initiatives analysis
Figure 17 Epilepsy drug market: Product movement analysis
Figure 18 Epilepsy drug market: Product outlook and key takeaways
Figure 19 First generation anti-epileptics market estimates and forecasts, 2018-2030 (USD Million)
Figure 20 Second generation anti-epileptics market estimates and forecasts, 2018-2030 (USD Million)
Figure 21 Third generation anti-epileptics market estimates and forecasts, 2018-2030 (USD Million)
Figure 22 Global epilepsy drug market: Regional movement analysis
Figure 23 Global epilepsy drug market: Regional outlook and key takeaways
Figure 24 North America market estimates and forecasts, 2018-2030 (USD Million)
Figure 25 U.S. market estimates and forecasts, 2018-2030 (USD Million)
Figure 26 Canada market estimates and forecasts, 2018-2030 (USD Million)
Figure 27 Europe market estimates and forecasts, 2018-2030 (USD Million)
Figure 28 UK market estimates and forecasts, 2018-2030 (USD Million)
Figure 29 Germany market estimates and forecasts, 2018-2030 (USD Million)
Figure 30 France market estimates and forecasts, 2018-2030 (USD Million)
Figure 31 Italy market estimates and forecasts, 2018-2030 (USD Million)
Figure 32 Spain market estimates and forecasts, 2018-2030 (USD Million)
Figure 33 Sweden market estimates and forecasts, 2018-2030 (USD Million)
Figure 34 Norway market estimates and forecasts, 2018-2030 (USD Million)
Figure 35 Denmark market estimates and forecasts, 2018-2030 (USD Million)
Figure 36 Asia-Pacific market estimates and forecasts, 2018-2030 (USD Million)
Figure 37 Japan market estimates and forecasts, 2018-2030 (USD Million)
Figure 38 China market estimates and forecasts, 2018-2030 (USD Million)
Figure 39 India market estimates and forecasts, 2018-2030 (USD Million)
Figure 40 Australia market estimates and forecasts, 2018-2030 (USD Million)
Figure 41 Thailand market estimates and forecasts, 2018-2030 (USD Million)
Figure 42 South Korea market estimates and forecasts, 2018-2030 (USD Million)
Figure 43 Latin America market estimates and forecasts, 2018-2030 (USD Million)
Figure 44 Brazil market estimates and forecasts, 2018-2030 (USD Million)
Figure 45 Mexico market estimates and forecasts, 2018-2030 (USD Million)
Figure 46 Argentina market estimates and forecasts, 2018-2030 (USD Million)
Figure 47 Middle East and Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 48 Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
Figure 49 South Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 50 UAE market estimates and forecasts, 2018-2030 (USD Million)
Figure 51 Kuwait market estimates and forecasts, 2018-2030 (USD Million)

Companies Mentioned

  • UCB S.A., Belgium
  • Sanofi
  • Pfizer, Inc.
  • Otsuka America Pharmaceutical, Inc.
  • Eisai Co., Ltd.
  • Novartis AG
  • Abbott Laboratories, Inc.
  • Sanofi Aventis S.A.
  • GlaxoSmithKline plc
  • Sunovion Pharmaceuticals, Inc.
  • Jazz Pharmaceuticals plc
  • Neurelis, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages91
PublishedDecember 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 10.15 Billion
Forecasted Market Value ( USD ) by 2030 $ 15.35 Billion
Compound Annual Growth Rate5.1%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Epilepsy Drugs Market Size and Forecasts 2020 - 2030, Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment, Distribution Channel, and Geography - Product Image

Epilepsy Drugs Market Size and Forecasts 2020 - 2030, Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment, Distribution Channel, and Geography

  • Report
  • 139 Pages
  • Global
From
Global Anti-Epileptic Drugs Market: Analysis By Drug Generation, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028 - Product Image

Global Anti-Epileptic Drugs Market: Analysis By Drug Generation, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028

  • Report
  • 159 Pages
  • Global
From
Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2024-2032 - Product Image

Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2024-2032

  • Report
  • 145 Pages
  • Global
From
Epilepsy Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Epilepsy Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 114 Pages
  • Global
From
Epilepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies Analysis - Product Image

Epilepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Top Companies Analysis

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.